NAD+: Mechanism, Dosing & Research Data

Storage Stability

Lyophilized

1–2 years (-20°C)

Reconstituted

N/A (oral)

Room temp

Stable (dry)

Mechanism of Action

Mitochondrial Energy Production

NAD+ accepts electrons from the citric acid cycle intermediates (NADH form), then donates them to Complex I of the electron transport chain. Without NAD+, mitochondria cannot efficiently produce ATP.

Sirtuin Activation

NAD+ is the obligate substrate for sirtuin" class="wiki-gloss-link">sirtuin deacetylases (SIRT1–7). Sirtuins regulate mitochondrial biogenesis (SIRT1 via PGC-1α), DNA repair (SIRT6), and metabolic homeostasis. Low NAD+ → low sirtuin activity → accelerated aging phenotypes.

PARP-Mediated DNA Repair

PARP enzymes consume NAD+ to add poly-ADP-ribose chains to DNA strand breaks, recruiting repair machinery. DNA damage (from oxidative stress, UV) depletes NAD+, a vicious cycle in aging cells.

CD38 Competition

CD38 (a major NAD+ consumer) increases with age and inflammation. CD38 competition is a key reason NAD+ declines with age beyond reduced biosynthesis.

Research Summary

Preclinical Longevity

NMN and NR supplementation in aged mice restores NAD+ levels, improves muscle function, reverses metabolic decline, and extends healthy lifespan in multiple studies.

IV NAD+ in Addiction Recovery

Off-label IV NAD+ (high-dose infusions 500–1,500 mg over 4–6 hours) is used in addiction clinics for withdrawal support, reporting improvements in energy, cognitive clarity, and craving reduction.

Human Phase I/II (NMN/NR)

Oral NMN (500 mg/day) and NR (300–1,000 mg/day) safely raise blood NAD+ levels in humans in multiple small RCTs. Functional outcomes in published trials are modest but consistent with NAD+ elevation.

Parkinson's & Neurodegeneration

Preclinical and small pilot data suggests NAD+ precursors may slow neurodegeneration through SIRT3/SIRT1 mitochondrial protection in dopaminergic neurons.

Calculate your NAD+ dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →

Research Protocols

IV Protocol

250–1,000 mg NAD+ in 500 mL saline infused over 2–4 hours. Faster infusion rate causes flushing, chest tightness, and GI discomfort. Must be given slowly. 3–5 days consecutively for "loading" series.

IM Protocol (Research Clinics)

100–500 mg IM daily for 10 days. Faster than IV but no rate control. Calculate draw volume carefully.

Oral Precursors

NMN 500 mg/day or NR 500 mg/day orally. Sublingual NMN may improve bioavailability. Take in the morning with food.

Storage & Handling

lyophilized" class="wiki-gloss-link">Lyophilized NAD+ powder: store at -20°C. Highly hygroscopic, keep sealed and dry. Reconstitute with sterile saline for IV. Use immediately after reconstitution. Do not store reconstituted solution. For IM use: reconstitute with sterile water or saline.

References

[1]Yoshino J, et al. "NAD+ and sirtuins in aging and disease." Trends Cell Biol, 2018.
[2]Rajman L, Chwalek K, Sinclair DA. "Therapeutic potential of NAD-boosting molecules." Cell Metab, 2018.
[3]Trammell SA, et al. "Nicotinamide riboside raises NAD+ in humans." Nat Commun, 2016.

Ready to dose NAD+?

Get the exact syringe draw

You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.

Open the Calculator →

Browse all peptides in the peptide library →

Evidence	C · Phase 1
Mol. weight	663.4 Da
Half-life	Very short (direct IV); precursors have hours-long kinetics
Peak time	,
Route(s)	IV / IM / Oral (as precursors NMN, NR)
Typical dose	250–1,000 mg (IV)
Frequency	2–3x weekly (IV therapy); daily (oral precursors)
Cycle	4 weeks IV series; ongoing oral
Storage	-20°C (freeze); room temp if dry powder
WADA	Not Listed Not on WADA prohibited list; no performance advantage classification
FDA	Not Approved (drug use) Not FDA-approved as a drug; IV NAD+ is off-label; NMN and NR are marketed as dietary supplements under DSHEA
Research	Preclinical / Early Phase I

NAD+